

# ABBVIE INC. NYSE-ABBV

RECENT PRICE **57.76**

P/E RATIO **17.3** (Trailing: 18.2 Median: NMF)

RELATIVE P/E RATIO **0.98**

DIV'D YLD **2.9%**

VALUE LINE

TIMELINESS —E  
SAFETY **2** New 7/12/13  
TECHNICAL —E  
BETA NMF (1.00 = Market)

LEGENDS  
... Relative Price Strength  
Options: Yes  
Shaded area indicates recession

High: 54.8  
Low: 33.3

Target Price Range  
2017 2018 2019

2017-19 PROJECTIONS  
Ann'l Total  
Price Gain Return  
High 75 (+30%) 9%  
Low 55 (-5%) 2%

Insider Decisions  
N D J F M A M J J  
to Buy 0 0 0 0 0 0 0 0  
Options 1 2 0 3 0 0 0 0  
to Sell 0 0 0 2 5 0 0 0

Institutional Decisions  
4Q2013 1Q2014 2Q2014  
to Buy 617 545 628  
to Sell 642 718 644  
Hld's(000) 108429010953041115375

Percent 21  
shares 14  
traded 7

% TOT. RETURN 9/14  
THIS STOCK VS. ARITH. INDEX  
1 yr. 33.5 9.5  
3 yr. — 84.2  
5 yr. — 104.4

1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 © VALUE LINE PUB. LLC 17-19

--	--	--	--	--	--	--	--	--	--	--	--	--	--	11.66	11.84	12.35	13.20	Sales per sh	14.45
--	--	--	--	--	--	--	--	--	--	--	--	--	--	4.48	3.44	3.45	4.10	"Cash Flow" per sh	4.70
--	--	--	--	--	--	--	--	--	--	--	--	--	--	4.13	3.14	3.15	3.80	Earnings per sh <sup>A</sup>	4.40
--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	1.60	1.66	1.76	Div'ds Decl'd per sh <sup>B</sup>	1.88
--	--	--	--	--	--	--	--	--	--	--	--	--	--	.21	.56	.50	.50	Cap'l Spending per sh	.50
--	--	--	--	--	--	--	--	--	--	--	--	--	--	2.13	2.83	3.75	5.85	Book Value per sh <sup>C</sup>	9.10
--	--	--	--	--	--	--	--	--	--	--	--	--	--	1577.0	1587.4	1590.0	1590.0	Common Shs Outst'g <sup>D</sup>	1590.0
--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	13.9	<i>Bold figures are Value Line estimates</i>		Avg Ann'l P/E Ratio	15.0
--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	.78			Relative P/E Ratio	.95
--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	3.7%			Avg Ann'l Div'd Yield	2.8%

CAPITAL STRUCTURE as of 6/30/14  
Total Debt \$14.5 bill. Due in 5 Yrs \$9.1 bill.  
LT Debt \$14.5 bill. LT Interest \$300 mill.  
(75% of Capital)

Pension Assets-12/13 \$3.7 bill. Oblig. \$4.5 bill.

Preferred Stock None

Common Stock 1,591,699,124 shares

MARKET CAP: \$91.9 billion (Large Cap)

CURRENT POSITION (\$MILL.)	2012	2013	6/30/14
Cash Assets	5901	9595	9086
Receivables	4298	3854	3684
Inventory (FIFO)	1091	1150	1048
Other	4064	3249	3976
Current Assets	15354	17848	17794
Accts Payable	5734	6448	6046
Debt Due	22	18	20
Other	1020	413	251
Current Liab.	6776	6879	6317

ANNUAL RATES of change (per sh)	Past 10 Yrs.	Past 5 Yrs.	Est'd '11-'13 to '17-'19
Sales	--	--	NMF
"Cash Flow"	--	--	NMF
Earnings	--	--	NMF
Dividends	--	--	NMF
Book Value	--	--	NMF

Cal-endar	QUARTERLY SALES (\$ mill.)				Full Year
	Mar.31	Jun.30	Sep.30	Dec.31	
2011	--	--	--	--	--
2012	4174	4493	4508	5205	18380
2013	4329	4692	4658	5111	18790
2014	4563	4926	4800	5311	19600
2015	4900	5100	5300	5700	21000

Cal-	EARNINGS PER SHARE <sup>A</sup>				Full
------	---------------------------------	--	--	--	------

**BUSINESS:** AbbVie Inc. is a global, research-based biopharmaceutical company that engages in the development and marketing of advanced therapies for some of the world's most complex diseases. Its products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis, low testosterone, thyroid disease, Parkinson's disease, ulcerative colitis, and chronic

**We have raised our 2014 estimates for AbbVie.** The revisions reflect the drug-maker's strong second-quarter performance (reported share earnings of \$0.82 versus our \$0.75 estimate). The beat was driven by another impressive showing from the company's cornerstone *HUMIRA* franchise, where sales surged 26% year over year to \$3.3 billion and now account for about 67% of the top line. While we would typically like to see more product diversity, *HUMIRA* is on a nice roll and shows no signs of slowing down. All told, we have raised our 2014 share-net target by a nickel, to \$3.15.

kidney disease, among other indications. Was formed 1/1/13 through a spinoff by Abbott Laboratories. Off'dirs. own less than 1% of common stock; BlackRock, 6.6%; Capital Research Global, 6.3%; Vanguard, 5.2% (3/14 proxy). Chrmn/CEO: Richard A. Gonzalez. Inc. DE. Addr.: 1 North Waukegan Rd, North Chicago, IL 60064. Tel.: 847-932-7900. Internet: www.abbvie.com.

fall to 13% for the combined entity by 2016. At this juncture, the companies are awaiting a decision from European regulators, who have until October 16th to decide whether or not to approve the transaction. The EU regulatory authority can either clear the deal unconditionally or demand concessions if it sees potential competition issues. **Recent changes in the U.S. could impact the deal's attractiveness.** With tax inversion deals becoming increasingly popular of late (where a U.S. company buys a foreign company strictly for tax benefits), the U.S. government announced changes in late September designed to close these

